re treated with the Genous stent.
Antiplatelet therapy was stopped five days prior to scheduled surgery in
all patients, with an average antiplatelet therapy duration of 12.5 days.
After NCS, thienopyridine administration was not restarted and 100 mg per
day of ASA was the only cardiac antiplatelet therapy at discharge. MACE,
including in-hospital cardiac death, MI, stent thrombosis, surgical
bleeding complications, need for revascularization and 30 day after surgery
clinical follow- up, were evaluated.
The results of the study indicated an optimal acute procedural result
in all patients. The 22 patients included in the study underwent uneventful
NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at
in-hospital follow-up and at one month follow-up.
"The Genous stent may offer a new, important and feasible therapeutic
strategy for patients needing to undergo life-saving or undeferrable major
noncardiac surgery early after coronary stent deployment," said Piscione.
Unlike drug-eluting stents, Genous, which is coated with an antibody,
captures a patient's EPCs to accelerate the natural healing process. EPCs
circulate in the bloodstream and are involved in the repair of blood
vessels. When attracted to the surface of Genous, EPCs rapidly form an
endothelial layer over the stent that provides protection against thrombus
and minimizes restenosis.
OrbusNeich designs, develops, manufactures and markets innovative
medical devices for the treatment of vascular diseases. The company's
product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an
antibody-coated device that is the first-ever stent to capture a patient's
endothelial progenitor cells (EPCs) to accelerate the natural healing
process following placement. Other products are stents, balloons and
guiding catheters marketed under the names of Blazer(TM), R stent(TM),
Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM),
Lumina(TM) and Saffron.
<Page: 1 2 3 Related medicine technology :1
. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)2
. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference3
. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia4
. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology5
. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie6
. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference7
. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress8
. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy9
. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis10
. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy11
. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy